Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

27 Sep 2023
www.biospace.com
ImmunotherapyCell Therapy
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc., (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023. Details of the poster presentation are as follows: Abstract Title: Assay Development and Quantitative Detection of ADI-001, a CD20-Targeted γδ1 CAR T Therapy, using AlloCell, a Universal Assay for Monitoring of “Off-the-Shelf" Allogeneic Cell Therapies Poster/Abstract Number: 684 Presenting Authors: Jackie Wilde, MS & Monica Moreno, PhD Date/Time: November 4, 2023, from 9:00 a.m. - 8:30 p.m. PDT Abstract Title: ADI-925: An Allogeneic “Off-the-Shelf" Chimeric Adapter (CAd) γδ T Cell Therapy Targeting NKG2D Ligand-Expressing Cancers Poster/Abstract Number: 265 Presenting Authors: Marissa Herrman, PhD Date/Time: November 3, 2023, from 9:00 a.m. - 8:30 p.m. PDT Abstract Title: Disruption of the Cytokine Signaling Checkpoint CIS Enhances Serial-Killing and Anti-Tumor Activity of CAR-Engineered γδ T Cells Poster/Abstract Number: 246 Presenting Authors: Beibei Ding, PhD Date/Time: November 4, 2023, from 9:00 a.m. - 8:30 p.m. PDT These abstracts will be available as a supplement in the Journal for ImmunoTherapy of Cancer (JITC) on Tuesday, October 31, 2023 at 9:00 a.m. EDT on . About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.